Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6900+0.0100 (+0.60%)
At close: 04:00PM EDT
1.6899 -0.00 (-0.01%)
After hours: 05:30PM EDT
Advertisement
Advertisement
Show:
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Breakdown
ttm
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
27,172
41,867
23,028
135,082
19,886
Cost of Revenue
9,193
7,266
-
-
-
Gross Profit
17,979
34,601
-
-
-
Operating Expense
133,121
122,136
112,111
129,697
131,565
Operating Income
-115,142
-87,535
-89,083
5,385
-111,679
Other Income Expense
3,479
2,061
642
2,334
4,490
Pretax Income
-111,663
-85,474
-88,441
7,719
-107,189
Tax Provision
-
0
0
-691
-816
Net Income Common Stockholders
-111,663
-85,474
-88,441
8,410
-106,373
Diluted NI Available to Com Stockholders
-111,663
-85,474
-88,441
8,410
-106,373
Basic EPS
-
-1.59
-1.74
0.18
-2.49
Diluted EPS
-
-1.59
-1.74
0.18
-2.49
Basic Average Shares
-
53,654
50,719
47,413
42,669
Diluted Average Shares
-
53,654
50,719
47,915
42,669
Total Operating Income as Reported
-115,142
-87,535
-89,083
5,385
-111,679
Total Expenses
142,314
129,402
112,111
129,697
131,565
Net Income from Continuing & Discontinued Operation
-111,663
-85,474
-88,441
8,410
-106,373
Normalized Income
-111,663
-85,474
-88,441
8,410
-106,373
EBIT
-115,142
-87,535
-89,083
5,385
-111,679
EBITDA
-114,902
-87,535
-89,083
5,594
-111,679
Reconciled Cost of Revenue
9,078
7,266
-
-
-
Reconciled Depreciation
240
248
248
209
198
Net Income from Continuing Operation Net Minority Interest
-111,663
-85,474
-88,441
8,410
-106,373
Normalized EBITDA
-114,902
-87,535
-89,083
5,594
-111,679
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
Advertisement
Advertisement